Hematologic Malignancies

• FDA approval · 2023-07-27
  FDA Approved: KEPIVANCE — Supplemental Application (Swedish Orphan Biovitrum AB (publ))

  The FDA approved a supplemental application for Kepivance (palifermin) from Swedish Orphan Biovitrum AB (publ). This action updates the prod…

• FDA approval · 2019-12-18
  FDA Approved: KEPIVANCE — Supplemental Application (Swedish Orphan Biovitrum AB (publ))

  FDA approved a supplemental application for KEPIVANCE (palifermin) filed by Swedish Orphan Biovitrum AB (publ), expanding its label for the …

• FDA approval · 2016-07-01
  FDA Approved: KEPIVANCE — Supplemental Application (Swedish Orphan Biovitrum AB (publ))

  FDA approved a supplemental application for Kepivance (palifermin) submitted by Swedish Orphan Biovitrum AB (publ).

• FDA approval · 2016-04-27
  FDA Approved: KEPIVANCE — Supplemental Application (Swedish Orphan Biovitrum AB (publ))

  The FDA approved a supplemental application for Kepivance (palifermin) filed by Swedish Orphan Biovitrum AB (publ). The action relates to la…

• FDA approval · 2011-11-14
  FDA Approved: KEPIVANCE — Supplemental Application (Swedish Orphan Biovitrum AB (publ))

  The FDA approved a supplemental application for Kepivance (palifermin) from Swedish Orphan Biovitrum AB (publ). The supplemental approval up…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.